A study involving patients with melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) indicated that elevated baseline CXCL8 levels in plasma were linked to poorer clinical outcomes in patients receiving immunotherapy (such as nivolumab or ipilimumab). Here, CXCL8 is linked to renal cell carcinoma.